GB0413510D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB0413510D0
GB0413510D0 GBGB0413510.9A GB0413510A GB0413510D0 GB 0413510 D0 GB0413510 D0 GB 0413510D0 GB 0413510 A GB0413510 A GB 0413510A GB 0413510 D0 GB0413510 D0 GB 0413510D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0413510.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB0413510.9A priority Critical patent/GB0413510D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of GB0413510D0 publication Critical patent/GB0413510D0/en
Priority to PE2005000677A priority patent/PE20060434A1/es
Priority to KR1020077001065A priority patent/KR20070029254A/ko
Priority to CN2005800195155A priority patent/CN1976718B/zh
Priority to DK05757953.4T priority patent/DK1758609T3/da
Priority to ES05757953T priority patent/ES2394448T3/es
Priority to MXPA06014515A priority patent/MXPA06014515A/es
Priority to PT57579534T priority patent/PT1758609E/pt
Priority to TW094119691A priority patent/TW200612983A/zh
Priority to EP05757953A priority patent/EP1758609B1/en
Priority to JP2007515878A priority patent/JP2008502633A/ja
Priority to US11/570,603 priority patent/US7758866B2/en
Priority to PCT/EP2005/006461 priority patent/WO2005123125A1/en
Priority to PL05757953T priority patent/PL1758609T3/pl
Priority to SG200904200-3A priority patent/SG153837A1/en
Priority to ARP050102434A priority patent/AR049354A1/es
Priority to RU2006143804/10A priority patent/RU2420313C2/ru
Priority to CA2566620A priority patent/CA2566620C/en
Priority to KR1020127027786A priority patent/KR101359943B1/ko
Priority to BRPI0512042A priority patent/BRPI0512042B8/pt
Priority to SI200531633T priority patent/SI1758609T1/sl
Priority to AU2005253723A priority patent/AU2005253723B2/en
Priority to IL179138A priority patent/IL179138A0/en
Priority to ZA200610057A priority patent/ZA200610057B/en
Priority to MA29576A priority patent/MA28692B1/fr
Priority to NO20070195A priority patent/NO20070195L/no
Priority to JP2012001102A priority patent/JP2012102132A/ja
Priority to HRP20120930TT priority patent/HRP20120930T1/hr
Priority to CY20121101211T priority patent/CY1113830T1/el
Priority to NL300773C priority patent/NL300773I1/nl
Priority to NL300771C priority patent/NL300771I2/nl
Priority to NL300774C priority patent/NL300774I1/nl
Priority to HUS1500059C priority patent/HUS1500059I1/hu
Priority to HUS1500061C priority patent/HUS1500061I1/hu
Priority to HUS1500060C priority patent/HUS1500060I1/hu
Priority to FR15C0082C priority patent/FR15C0082I2/fr
Priority to FR15C0080C priority patent/FR15C0080I2/fr
Priority to FR15C0084C priority patent/FR15C0084I2/fr
Priority to CY2015049C priority patent/CY2015049I2/el
Priority to CY2015048C priority patent/CY2015048I1/el
Priority to LTPA2015046C priority patent/LTC1758609I2/lt
Priority to CY2015047C priority patent/CY2015047I2/el
Priority to LU92900C priority patent/LU92900I2/xx
Priority to LU92898C priority patent/LU92898I2/xx
Priority to LU92899C priority patent/LU92899I2/xx
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB0413510.9A 2004-06-16 2004-06-16 Vaccine Ceased GB0413510D0 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
AU2005253723A AU2005253723B2 (en) 2004-06-16 2005-06-14 Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2007515878A JP2008502633A (ja) 2004-06-16 2005-06-14 Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
CN2005800195155A CN1976718B (zh) 2004-06-16 2005-06-14 抗hpv16和hpv18和至少一种另外的选自hpv31、45或52的hpv类型的疫苗
DK05757953.4T DK1758609T3 (da) 2004-06-16 2005-06-14 Vaccine mod HPV 16 og HPV 18 og mindst en anden HPV-type udvalgt blandt HPV 31, 45 eller 52
ES05757953T ES2394448T3 (es) 2004-06-16 2005-06-14 Vacuna contra VPH16 yVPH18 y al menos otro tipo de VPH seleccionado de entre VPH 31, 45 o 52
MXPA06014515A MXPA06014515A (es) 2004-06-16 2005-06-14 Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
PT57579534T PT1758609E (pt) 2004-06-16 2005-06-14 Vacina contra hpv16 e hpv18 e, pelo menos, outro tipo de hpv seleccionado de hpv31, 45 ou 52
TW094119691A TW200612983A (en) 2004-06-16 2005-06-14 Vaccine
EP05757953A EP1758609B1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
PE2005000677A PE20060434A1 (es) 2004-06-16 2005-06-14 Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US11/570,603 US7758866B2 (en) 2004-06-16 2005-06-14 Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR1020077001065A KR20070029254A (ko) 2004-06-16 2005-06-14 Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
PL05757953T PL1758609T3 (pl) 2004-06-16 2005-06-14 Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
SG200904200-3A SG153837A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
ARP050102434A AR049354A1 (es) 2004-06-16 2005-06-14 VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN
RU2006143804/10A RU2420313C2 (ru) 2004-06-16 2005-06-14 Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
CA2566620A CA2566620C (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
KR1020127027786A KR101359943B1 (ko) 2004-06-16 2005-06-14 Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는 52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
BRPI0512042A BRPI0512042B8 (pt) 2004-06-16 2005-06-14 composição imunogênica, vacina, uso de uma composição ou vacina, método para produzir uma composição imunogênica, e, uso de vlps ou capsômeros de hpv 16 e 18 com vlps ou capsômeros de pelo menos um outro hpv do tipo causador de câncer
SI200531633T SI1758609T1 (sl) 2004-06-16 2005-06-14 Cepivo proti HPV16 in HPV18 in vsaj še enemu tipu HPV, izbranemu izmed HPV 31, 45 ali 52
IL179138A IL179138A0 (en) 2004-06-16 2006-11-09 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
ZA200610057A ZA200610057B (en) 2004-06-16 2006-11-30 Vassine against HPV 16 and HPV 18 and at least another HPV type selected from HPV 31, 45 or 52
MA29576A MA28692B1 (fr) 2004-06-16 2006-12-28 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
NO20070195A NO20070195L (no) 2004-06-16 2007-01-11 Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
JP2012001102A JP2012102132A (ja) 2004-06-16 2012-01-06 Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
HRP20120930TT HRP20120930T1 (hr) 2004-06-16 2012-11-16 Cjepivo protiv hpv16 i hpv18 i još najmanje jednog tipa hpv, kojeg se bira između hpv31, 45 ili 52
CY20121101211T CY1113830T1 (el) 2004-06-16 2012-12-11 Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
NL300773C NL300773I1 (nl) 2004-06-16 2015-11-30
NL300771C NL300771I2 (nl) 2004-06-16 2015-11-30
NL300774C NL300774I1 (nl) 2004-06-16 2015-11-30
HUS1500059C HUS1500059I1 (hu) 2004-06-16 2015-12-01 A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
HUS1500061C HUS1500061I1 (hu) 2004-06-16 2015-12-01 A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
HUS1500060C HUS1500060I1 (hu) 2004-06-16 2015-12-01 A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
FR15C0082C FR15C0082I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
FR15C0084C FR15C0084I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
FR15C0080C FR15C0080I2 (fr) 2004-06-16 2015-12-04 Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
CY2015049C CY2015049I2 (el) 2004-06-16 2015-12-07 Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
CY2015048C CY2015048I1 (el) 2004-06-16 2015-12-07 Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
LTPA2015046C LTC1758609I2 (lt) 2004-06-16 2015-12-07 Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31,45 arba 52
CY2015047C CY2015047I2 (el) 2004-06-16 2015-12-07 Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
LU92900C LU92900I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
LU92898C LU92898I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31
LU92899C LU92899I2 (fr) 2004-06-16 2015-12-08 Gardasil-9/vaccination contre les stéréotypes 16,18 et 31 nom de produit: hpv l1 vlps 16+18+31

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine

Publications (1)

Publication Number Publication Date
GB0413510D0 true GB0413510D0 (en) 2004-07-21

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0413510.9A Ceased GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine

Country Status (15)

Country Link
JP (1) JP2012102132A (nl)
KR (1) KR101359943B1 (nl)
CN (1) CN1976718B (nl)
CY (1) CY1113830T1 (nl)
DK (1) DK1758609T3 (nl)
ES (1) ES2394448T3 (nl)
GB (1) GB0413510D0 (nl)
HR (1) HRP20120930T1 (nl)
HU (3) HUS1500060I1 (nl)
LT (1) LTC1758609I2 (nl)
NL (3) NL300771I2 (nl)
PT (1) PT1758609E (nl)
SI (1) SI1758609T1 (nl)
TW (1) TW200612983A (nl)
ZA (1) ZA200610057B (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
EP2593548A4 (en) * 2010-07-15 2013-11-27 British Columbia Cancer Agency ANTIGEN E7 COMPOSITIONS OF HUMAN PAPILLOMAVIRUS AND USES THEREOF
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
PT1758609E (pt) 2012-12-21
NL300771I1 (nl) 2015-12-29
CN1976718B (zh) 2012-10-10
HUS1500061I1 (hu) 2016-01-28
NL300774I2 (nl) 2015-12-29
NL300771I2 (nl) 2015-12-29
LTC1758609I2 (lt) 2017-05-10
HRP20120930T1 (hr) 2012-12-31
CN1976718A (zh) 2007-06-06
TW200612983A (en) 2006-05-01
ZA200610057B (en) 2008-02-27
KR101359943B1 (ko) 2014-02-10
HUS1500060I1 (hu) 2017-10-30
ES2394448T3 (es) 2013-01-31
CY1113830T1 (el) 2016-06-22
SI1758609T1 (sl) 2013-01-31
NL300773I2 (nl) 2015-12-29
NL300774I1 (nl) 2015-12-29
KR20120123617A (ko) 2012-11-08
JP2012102132A (ja) 2012-05-31
NL300773I1 (nl) 2015-12-29
HUS1500059I1 (hu) 2017-10-30
DK1758609T3 (da) 2012-12-10

Similar Documents

Publication Publication Date Title
TWI365191B (en) Vaccine
GB2434367B (en) Improved vaccines
IL178890A0 (en) Vaccines
IL192084A0 (en) Vaccine
GB0504436D0 (en) Vaccine
GB0409940D0 (en) Vaccine
GB0420634D0 (en) Vaccines
GB0411150D0 (en) Vaccine
GB0515135D0 (en) Vaccine
ZA200709207B (en) Vaccine
GB0516944D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0810662D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
AP2709A (en) An anti-theileriosis vaccine
GB0526412D0 (en) Vaccine
GB0413513D0 (en) Vaccine
GB0416398D0 (en) Vaccine
GB0425339D0 (en) Vaccine
GB0413371D0 (en) Vaccine
GB0416833D0 (en) Vaccine
GB0413154D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)